UnitedHealth scraps Medicare Advantage commissions: will UNH stock benefit?

UnitedHealth Group (UNH) is eliminating broker commissions on some Medicare Advantage plans to lower costs and improve profitability, a move that could positively impact its stock. The decision aims to reduce enrollment in higher-cost plans, addressing a significant administrative expense that contributed to derailing its financials and forcing management to pull full-year guidance in May. Despite potential regulatory challenges, Stephanie Link at Hightower recommends owning UNH shares, citing its unprecedented discount at a P/E of 13 and the potential for a stock buyback program to boost its value; Wall Street has an "overweight" rating on UNH with a mean price target of $364.

Analysis

UnitedHealth Group (UNH) is strategically eliminating broker commissions on certain Medicare Advantage plans to mitigate rising costs and enhance profitability. This measure directly targets the higher-than-expected expenses within its Medicare Advantage segment, which notably led to the withdrawal of its full-year guidance in May and has contributed to the stock trading approximately 50% below its all-time high. By removing these commissions, UNH aims to reduce enrollment in its higher-cost plans, thereby addressing a significant administrative expense that has been a factor in projections of derailing its financials into 2025. While this could result in a marginal decrease in overall enrollment, the company anticipates a leaner, more profitable business structure. Despite these proactive steps, persistent regulatory challenges continue to loom. The return of Stephen Hemsley, who previously led the company as CEO from 2006 to 2017, to a top role is viewed positively. Furthermore, Hightower's Stephanie Link highlights the stock's current price-to-earnings multiple of 13 as an "unprecedented discount" and points to UNH's strong balance sheet with potential for an extended stock buyback program, which could aid share recovery in the second half of 2025. Wall Street reflects a generally optimistic view with a consensus "overweight" rating and a mean price target of approximately $364, indicating a potential 18% upside, while the stock has already appreciated by 13% from its year-to-date low.

Key Decisions for Investors

• Investors could view the current discounted valuation and the proactive cost-reduction measures as a compelling opportunity, particularly given the analyst consensus for potential upside, while remaining cognizant of ongoing regulatory headwinds.
• It is advisable to closely monitor the impact of the commission removal strategy on Medicare Advantage enrollment trends, overall cost structures, and resulting profitability in forthcoming quarters.
• The combination of experienced leadership returning, the prospect of a significant stock buyback program, and UNH's robust balance sheet may present a case for long-term investment, provided investors are prepared to navigate potential near-term market volatility.